Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00068289 · ClinicalTrials.gov registry record · Phase 2
Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00068289: Completed Phase 2 study, sponsored by SWOG Cancer Research Network.
NCT00068289 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00068289, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have recurrent or refractory extensive-stage small cell lung cancer that was previously treated with platinum-based chemotherapy (such as cisplatin, carboplatin, or oxaliplatin).
Interventions
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-09 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
What the finished NCT00068289 record still lists
NCT00068289 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which bortezomib is the first listed.
NCT00068289 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00068289 about?
NCT00068289 is a clinical study titled "Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy". RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have recurrent or refractory extensive-stage small cell lung cancer that was previously treated with...
What is the current status of trial NCT00068289?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-09. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00068289?
The interventions under investigation include: bortezomib (DRUG).
Who is sponsoring clinical trial NCT00068289?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia